

Version 6.7	Revision Date: 28.09.2024		S Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014	
SECTION	1. IDENTIFICATION				
Produ	Product identifier		Timolol / Dorzolamide Formulation		
Manu	Ifacturer or supplier's	deta	ils		
Com	bany	:	MSD		
Address		:	Avenue Comendador Antônio Loureiro Ramos, nº 1500 – Distrito Industrial Montes Claros – MG, Brazil 39404-620		
Telep	Telephone		+55 (38) 3229 7000		
Emer	Emergency telephone		+55 (38) 3201 5670		
E-mail address : EHSDATAS			EHSDATASTEV	VARD@msd.com	
Recommended use of the chem			emical and restrictions on use		
Recommended use Restrictions on use			Pharmaceutical Not applicable		

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard						
Specific target organ toxicity - : repeated exposure	Category 1 (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs)					
GHS label elements in accorda	nce with ABNT NBR 14725 Standard					
Hazard pictograms :						
Signal Word :	Danger					
Hazard Statements :	H372 Causes damage to organs (Cardio-vascular system, Cen- tral nervous system, Gastrointestinal tract, Lungs) through pro- longed or repeated exposure.					
Precautionary Statements :	Prevention:					
	P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.					
	Response:					
	P314 Get medical advice/ attention if you feel unwell.					





Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.7	28.09.2024	28795-00023	Date of first issue: 06.11.2014

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Dorzolamide	130693-82-2	Acute Tox. (Oral), 4 STOT RE, (Central nervous system, Gas- trointestinal tract, Bone, Blood, Blad- der), 2	>= 1 -< 5
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	Acute Tox. (Oral), 4 Repr., 2 STOT RE, (Lungs, Cardio-vascular sys- tem), 1	>= 0,1 -< 1

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.
		Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam



Ver 6.7	sion	Revision Date: 28.09.2024		S Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
				Carbon dioxide (C Dry chemical	:02)
	Unsuitable extinguishing media		:	None known.	
	Specific hazards during fire fighting		:	Exposure to comb	pustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Nitrogen oxides (f Sulfur oxides Hydrogen chloride	
	Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area.	
	Special for fire-f	protective equipment ighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SAFETY DATA SHEET



Timolol / Dorzolamide Formulation

Version 6.7	Revision Date: 28.09.2024	SDS Number: 28795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014			
SECTION	N 7. HANDLING AND ST	ORAGE				
Technical measures Local/Total ventilation Advice on safe handling Hygiene measures		CONTROLS/PEF Use only with add Do not breathe m Do not swallow. Avoid contact wit Avoid prolonged Wash skin thorou Handle in accord practice, based o assessment Do not eat, drink Take care to prevenvironment. If exposure to che	h eyes. or repeated contact with skin. ghly after handling. ance with good industrial hygiene and safety n the results of the workplace exposure or smoke when using this product. rent spills, waste and minimize release to the emical is likely during typical use, provide eye			
		place. When using do n Wash contaminat The effective ope engineering contr appropriate dego industrial hygiene use of administra	When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.			
Materials to avoid Store in ac Store in ac Do not sto Strong oxi			stances and mixtures			

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Dorzolamide	130693-82-2	TWA	10 µg/m3 (OEB 3)	Internal
	Further informa	ation: Eye		
		Wipe limit	100 µg/100 cm ²	Internal
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	TWA	10 µg/m3 (OEB 3)	Internal
	Further information: Eye, Skin			
		Wipe limit	100 µg/100 cm ²	Internal

Engineering measures : Us

: Use appropriate engineering controls and manufacturing



Version 6.7	Revision Date: 28.09.2024		DS Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014	
			technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compour are required to control at source and to prevent migration the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.		
Per	rsonal protective equipm	nent			
Respiratory protection Filter type Hand protection		:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Particulates type		
Material		:	Chemical-resistant gloves		
mists or aerosols, wear the approp Wear a faceshield or other full face potential for direct contact to the fa		ses with side shields or goggles. nment or activity involves dusty conditions,			
Skin and body protection		:	aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon th task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove poten contaminated clothing.		

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	liquid
Color	:	colorless
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	5,6
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available

SAFETY DATA SHEET



Timolol / Dorzolamide Formulation

Vers 6.7	sion	Revision Date: 28.09.2024	-	S Number: 95-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	pressure	:	No data available	
	Relative	e vapor density	:	No data available	
	Relative	e density	:	1,02	
	Density		:	No data available	
	Solubili Wat	ty(ies) er solubility	:	soluble	
	Partition octanol	n coefficient: n-	:	No data available	
		ition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	Viscosi Visc	ty osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	
	Particle Particle	characteristics size	:	No data available	

SECTION 10. STABILITY AND REACTIVITY

:	Not classified as a reactivity hazard.
:	Stable under normal conditions.
:	Can react with strong oxidizing agents.
:	None known.
:	Oxidizing agents
:	No hazardous decomposition products are known.
	:

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation



rsion '	Revision Date: 28.09.2024		S Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
expos	ure		Skin contact Ingestion Eye contact	
	e toxicity assified based on availa	ble	information.	
<u>Produ</u> Acute	<u>ict:</u> oral toxicity	:	Acute toxicity esti Method: Calculati	mate: > 5.000 mg/kg on method
Comp	oonents:			
	olamide:			
Acute	oral toxicity	:	LD50 (Rat): 1.927	′ mg/kg
			LD50 (Mouse): 1.	320 mg/kg
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	dermal toxicity	:	Remarks: No data	a available
• •	[3-(tert-butylamino)-2-ł oral toxicity	nyd :	r oxypropoxy]-4-n LD50 (Rat): 1.000	norpholino-1,2,5-thiadiazole monomalea
,			LD50 (Mouse): 1.	
	toxicity (other routes of istration)	:)0 mg/kg
			LD50 (Mouse): 80 Application Route	
	corrosion/irritation assified based on availa	hle	information	
	onents:	510		
		nyd	roxypropoxy1-4-m	orpholino-1,2,5-thiadiazole monomalea
Specie Metho Resul	es od	:	Rabbit Draize Test No skin irritation	· · · · · · · · · · · · · · · · · · ·
Serio	us eye damage/eye irri	tati	on	
	assified based on availa			

Dorzolamide:

Species	:	Monkey
Result	:	Mild eye irritation



ersion 7	Revision Date: 28.09.2024	SDS Number: 28795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
(S)-3-[3 Species Result		- 2-hydroxypropoxy]-4 : Rabbit : Mild eye irritati	I-morpholino-1,2,5-thiadiazole monomaleate
Specie: Result	S	: Dog : No eye irritatio	n
Respira	atory or skin sens	itization	
	ensitization ssified based on av	ailable information.	
-	atory sensitizatior ssified based on av		
Compo	onents:		
Dorzol Test Ty Routes Species Result	vpe of exposure	: Maximization T : Skin contact : Guinea pig : Weak sensitize	
Not cla	c ell mutagenicity ssified based on av onents: amide:	ailable information.	
Genoto	oxicity in vitro	: Test Type: Chr Result: negativ	romosomal aberration re
		Test Type: Alka Test system: ra Result: negativ	
			itro mammalian cell gene mutation test chinese hamster fibroblasts re
		Test Type: Bao Result: negativ	cterial reverse mutation assay (AMES)
Genoto	oxicity in vivo	: Test Type: Cyt Species: Mous Result: negativ	e
(S)-3-[3	B-(tert-butylamino)	-2-hydroxypropoxy]-4	I-morpholino-1,2,5-thiadiazole monomaleate
		: Test Type: Bad	cterial reverse mutation assay (AMES)
Genotc	oxicity in vitro		Test Guideline 471



sion	Revision Date: 28.09.2024	SDS Number: 28795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
		Method: OECI Result: negativ	D Test Guideline 474 /e
	nogenicity		
-	assified based on ava	liable information.	
Comp	oonents:		
Dorzo	plamide:		
Speci		: Rat, male	
	ation Route	: Oral	
Expos	sure time	: 2 Years	
		: 20 mg/kg body	v weight
Resul		: negative	
Rema	rks	: The mechanis mans.	m or mode of action may not be relevant in h
Speci	es	: Mouse	
Applic	ation Route	: Oral	
Expos	sure time	: 21 month(s)	
Resul	t	: negative	
(S)-3-	[3-(tert-butylamino)-2	2-hydroxypropoxy]-⁄	4-morpholino-1,2,5-thiadiazole monomale
Speci	es	: Rat	
	ation Route	: Oral	
	sure time	: 2 Years	
LOAE	L	: 300 mg/kg boo	ly weight
Resul	t	: negative	
Targe	t Organs	: Adrenal gland	
Rema	rks	: The significant	ce of these findings for humans is not certain
Speci		: Mouse, female	9
	ation Route	: Oral	
	sure time	: 18 Months	
LOAE		: 500 mg/kg boo	ly weight
Resul		: negative	any global literus (including comity)
Rema	t Organs		ary gland, Uterus (including cervix) ce of these findings for humans is not certain
rema	1173	. The significant	ce of these mounds for numaris is not certain
Carcir ment	nogenicity - Assess-	: Weight of evid cinogen	ence does not support classification as a car
Repro	oductive toxicity		
-	assified based on ava	ilable information.	
<u>Comp</u>	oonents:		
Dorzo	olamide:		
Effect	s on fertility	: Test Type: Fe	
			male and female
		Application Ro	
			L: 7,5 mg/kg body weight
		Result: Anima	testing did not show any effects on fertility.



rsion	Revision Date: 28.09.2024		0S Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
Effect	ts on fetal development	:	Result: Embryote spring were dete Test Type: Deve Species: Rabbit Application Rout Developmental T Result: Embryote	e: Oral Foxicity: NOAEL: 1 mg/kg body weight oxic effects and adverse effects on the off- ected only at high maternally toxic doses
(S)-3-	[3-(tert-butylamino)-2-	-hyd	roxypropoxy]-4-	morpholino-1,2,5-thiadiazole monomaleate
Effect	ts on fertility	:	Species: Rat Application Rout Fertility: NOAEL	ity/early embryonic development e: Oral Mating/Fertility: 150 mg/kg body weight Development: NOAEL F1: 150 mg/kg body
Effect	ts on fetal development	:	Species: Rabbit Developmental	ryo-fetal development Foxicity: LOAEL F1: 50 mg/kg body weight ridence of adverse effects on development, I experiments.
Repro sessn	oductive toxicity - As- nent	:	Some evidence animal experime	of adverse effects on development, based on ents.
	F-single exposure lassified based on avail	able	information.	
STOT	-repeated exposure			
	es damage to organs (C Lungs) through prolong			n, Central nervous system, Gastrointestinal ure.
Prod Targe	uct: et Organs	:	Cardio-vascular tinal tract, Lungs	system, Central nervous system, Gastrointes
Asses	ssment	:		to organs through prolonged or repeated
<u>Com</u>	oonents:			
Dorzo	olamide:			
Targe	et Organs	:	Central nervous Bladder	system, Gastrointestinal tract, Bone, Blood,



sion	Revision Date: 28.09.2024	SDS Number: 28795-00023	Date of first issue: 06.11.2014
(S)-3-	[3-(tert-butylamino)-2-hydroxypropoxy]-	4-morpholino-1,2,5-thiadiazole monomale
• •	t Organs		-vascular system
	ssment		ge to organs through prolonged or repeated
Repe	ated dose toxicity		
<u>Comp</u>	oonents:		
Dorzo	plamide:		
Speci		: Rat	
NOAE		: 0,05 mg/kg	
	ation Route	: Oral	
Targe	t Organs	: Bladder, Kidne	ey .
Speci		: Dog	
NOAE		: 0,05 mg/kg	
LOAE		: 2 mg/kg	
	cation Route	: Oral	
	sure time	: 1 y	al tract Dana Dlaad
Targe	t Organs	Gastrointestina	al tract, Bone, Blood
Snaai	es	: Monkey	
Speci			
NOAE		: 0,05 mg/kg	
NOAE Expos	EL sure time	: 0,05 mg/kg : 1 y	
NOAE Expos	EL	: 0,05 mg/kg : 1 y	al tract, Bone, Blood
NOAE Expos Targe (S)-3-	EL sure time t Organs [3-(tert-butylamino)	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-/	al tract, Bone, Blood 4-morpholino-1,2,5-thiadiazole monomale
NOAE Expos Targe (S)-3- Speci	EL sure time t Organs [3-(tert-butylamino) es	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat	
NOAE Expos Targe (S)-3- Speci NOAE	EL sure time It Organs [3-(tert-butylamino) es EL	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg	
NOAE Expos Targe (S)-3- Speci NOAE Applic	EL sure time t Organs [3-(tert-butylamino) es EL cation Route	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]- : Rat : 25 mg/kg : Oral	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time	: 0,05 mg/kg : 1 y : Gastrointestina -2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]- : Rat : 25 mg/kg : Oral : 67 Weeks : Dog	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]- : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : Oral	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : Oral : 54 Weeks	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : Oral	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos Targe	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : Oral : 54 Weeks	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos Targe	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time t Organs	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos Targe Aspir Not cl	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time t Organs ation toxicity	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information.	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Speci NOAE Applic Expos Targe Aspir Not cl	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time it Organs ation toxicity assified based on av rience with human	: 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information.	
NOAE Expose Targe (S)-3- Speci NOAE Applic Expose Targe Aspir Not cl Expose Targe	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time at Organs ation toxicity assified based on av rience with human	: 0,05 mg/kg : 1 y : Gastrointestina -2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information. exposure	4-morpholino-1,2,5-thiadiazole monomale
NOAE Expose Targe (S)-3- Speci NOAE Applic Expose Targe Aspir Not cl Expose Targe	EL sure time it Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time it Organs ation toxicity assified based on av rience with human	 : 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information. exposure : Symptoms: The burning or stin Dizziness, dige 	
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Targe Aspir Not cl Expec Produ Eye c	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time at Organs ation toxicity assified based on av rience with human	 : 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information. exposure : Symptoms: The burning or stin Dizziness, dige 	4-morpholino-1,2,5-thiadiazole monomale e most common side effects are:, bitter taste ging of the eye, Blurred vision, Abdominal pa estive disorder, eye pain, Headache, hyperte
NOAE Expos Targe (S)-3- Speci NOAE Applic Expos Targe Aspir Not cl Exper Produ Eye c	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time t Organs ation toxicity assified based on av rience with human <u>Jct:</u> ontact	 : 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information. exposure : Symptoms: The burning or stin Dizziness, dige 	4-morpholino-1,2,5-thiadiazole monomale e most common side effects are:, bitter taste ging of the eye, Blurred vision, Abdominal pa estive disorder, eye pain, Headache, hyperte
NOAE Expose Targe (S)-3- Speci NOAE Applic Expose Speci NOAE Applic Expose Targe Aspir Not cl Expose Targe Aspir Not cl Expose Targe Dorze	EL sure time t Organs [3-(tert-butylamino) es EL cation Route sure time es EL cation Route sure time t Organs ation toxicity assified based on av rience with human <u>Jct:</u> ontact	 : 0,05 mg/kg : 1 y : Gastrointestina)-2-hydroxypropoxy]-4 : Rat : 25 mg/kg : Oral : 67 Weeks : Dog : 10 mg/kg : Oral : 54 Weeks : Kidney vailable information. exposure : Symptoms: The burning or stin Dizziness, digasion, Nausea, 	4-morpholino-1,2,5-thiadiazole monomale e most common side effects are:, bitter taste ging of the eye, Blurred vision, Abdominal pa estive disorder, eye pain, Headache, hyperte



ersion 7	Revision Date: 28.09.2024		9S Number: 795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
			ing, asthenia, bitte	er taste, Nausea, dry mouth, Headache
(S)-3-	[3-(tert-butylamino)-2-l	hyd	roxypropoxy]-4-m	orpholino-1,2,5-thiadiazole monomaleat
Eye c	ontact	:	Symptoms: burnir eyes, Headache, libido, hair loss, A	ng or stinging of the eye, dryness of the Nausea, Dizziness, dry mouth, changes in Ilergic reactions
Ingest	tion	:	trointestinal disco	ache, Fatigue, Respiratory disorders, Gas- mfort, Allergic reactions, Rash, hair loss, atus, Dizziness, changes in libido
ECTION	12. ECOLOGICAL INFO	DRN	IATION	
Ecoto	oxicity			
<u>Comp</u>	oonents:			
Dorzo	olamide:			
Toxici	ty to fish	:	LC50 (Pimephale Exposure time: 96	s promelas (fathead minnow)): > 1.000 mg/ 5 h
	ty to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48	nagna (Water flea)): 699 mg/l 3 h
Toxici	ty to microorganisms	:	EC50 (Natural mi Exposure time: 3	croorganism): > 800 mg/l h
			Test Type: Respir Method: OECD T	ation inhibition
(S)-3-	[3-(tert-butylamino)-2-I	hyd	roxypropoxy]-4-m	orpholino-1,2,5-thiadiazole monomaleat
Toxici	ty to fish	:	LC50 (Pimephale Exposure time: 96	s promelas (fathead minnow)): 411 mg/l 5 h
	ty to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48	hagna (Water flea)): 161 mg/l
aquat	in invertebrates		Method: OECD T	
Toxici	ty to microorganisms	:	EC50: > 1.000 mg	
			Exposure time: 3 Test Type: Respir	
				erium phosphoreum): > 1.800 mg/l
Poreio	stence and degradabili	itv		
	oonents:	.,		
	plamide:			
	gradability	:	Result: not rapidly Biodegradation: { Exposure time: 28	5%
			Method: OECD T	

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:



Versio 6.7	on	Revision Date: 28.09.2024		DS Number: 8795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014
B	liodeg	radability	:	Result: Not readil Biodegradation: (Exposure time: 30)%
S	Stability	/ in water	:	Hydrolysis: 0 %(6 Method: FDA 3.09	
В	Bioacc	umulative potential			
<u>c</u>	ompo	onents:			
D	orzol	amide:			
P	artitio	n coefficient: n- /water	:	log Pow: 0,292	
(5	S)-3-[3	B-(tert-butylamino)-2-	hyd	lroxypropoxy]-4-m	orpholino-1,2,5-thiadiazole monomaleate:
		n coefficient: n- /water	:	log Pow: 1,48	
М	lobilit	y in soil			
Ν	lo data	a available			
о)ther a	adverse effects			
Ν	lo data	a available			
	-	3. DISPOSAL CONSI	DEF	RATIONS	
	•	al methods			
W	Vaste	from residues	:		waste into sewer. ordance with local regulations.
С	Contam	ninated packaging	:	Empty containers handling site for r	should be taken to an approved waste ecycling or disposal. becified: Dispose of as unused product.
SECTI	ION 1	4. TRANSPORT INFO	RM	IATION	
In	nterna	tional Regulations			
	INRTE lot reg)G ulated as a dangerous	s go	od	
	ATA-D lot reg	IGR ulated as a dangerous	s go	od	

IMDG-Code Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable





Version 6.7	Revision Date: 28.09.2024	SDS Number: 28795-00023	Date of last issue: 30.09.2023 Date of first issue: 06.11.2014	
SECTIO	ON 15. REGULATORY INF	ORMATION		
	fety, health and environn xture	nental regulations/leg	islation specific for the substance or	
	tional List of Carcinogenic NACH)	Agents for Humans -	: Not applicable	
	Brazil. List of chemicals controlled by the Federal : Not applicable Police			
Th	e ingredients of this proc	duct are reported in th	ne following inventories:	
AIC	CS	: not determined		
DS	L	: not determined		
IEC	CSC	: not determined		
SECTIC	ON 16. OTHER INFORMA	ΓΙΟΝ		

Revision Date	:	28.09.2024
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety	eChem Portal search results and European Chemicals Agen-
Data Sheet	cy, http://echa.europa.eu/

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.7	28.09.2024	28795-00023	Date of first issue: 06.11.2014

lative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8